默沙东的Winrevair在三期临床试验中取得成功,显著降低肺动脉高压患者的发病和死亡风险。医药板块整体表现强劲,涨幅达3.34%,跑赢沪深300指数3.33个百分点,其中生物制品、体外诊断和疫苗子行业表现尤为突出。个股方面,海创药业-U、欧康医药和欧林生物领涨,分别上涨16.9%、10.87%和5.11%。资金流入方面,锦波生物、凯因科技和百奥泰净流入居前。乐普医疗宣布其自主研发的冠脉棘突球囊...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.